The stock of Sanofi (NASDAQ:SNY) last traded at $52.48, down -1.98% from the previous session.
SNY stock price is now -0.43% away from the 50-day moving average and 6.29% away from the 200-day moving average. The market capitalization of the company currently stands at $136.99B.
A total of 16.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SNY stock. A new stake in Sanofi shares was purchased by PERCEPTIVE ADVISORS LLC during the first quarter worth $40,310,000. CAPITAL WORLD INVESTORS invested $32,849,000 in shares of SNY during the first quarter. In the first quarter, OLD MISSION CAPITAL, LLC acquired a new stake in Sanofi valued at approximately $18,527,000. ROKOS CAPITAL MANAGEMENT LLP acquired a new stake in SNY for approximately $14,262,000. JEFFERIES GROUP LLC purchased a new stake in SNY valued at around $11,241,000 in the second quarter. In total, there are 761 active investors with 10.30% ownership of the company’s stock.
With an opening price of $51.87 on Friday morning, Sanofi (NASDAQ: SNY) set off the trading day. During the past 12 months, Sanofi has had a low of $36.91 and a high of $57.82. As of last week, the company has a debt-to-equity ratio of 0.29, a current ratio of 1.20, and a quick ratio of 0.80. According to the stock market information, the enterprise value for the company is $144.99B, which is based on a 14.39 price-to-earnings ratio, a 2.21 price-to-earnings-growth ratio, and a beta of 0.56. The fifty day moving average price for SNY is $52.67 and a two-hundred day moving average price translates $49.44 for the stock.
The latest earnings results from Sanofi (NASDAQ: SNY) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.16, missing analysts’ expectations of $1.88 by -0.72. This compares to $0.91 EPS in the same period last year. The company reported revenue of $11.66 billion for the quarter, compared to $11.28 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 3.36 percent. For the current quarter, analysts expect SNY to generate $11.23B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/23/2023. Investors who held shares on 05/31/2023 were paid a $1.9000852 dividend. On an annualized basis, this represents a $1.90 dividend and a 3.62% percent yield. There was an ex-dividend date of 05/30/2023 for this dividend. In terms of dividend payout ratio, SNY is presently at 53.27%.
Sanofi(SNY) Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson’s disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
